- Home
- NAAS vs KPRX Comparison
NAAS vs KPRX Comparison
Compare NAAS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- KPRX
- Stock Information
- Founded
- NAAS 2019
- KPRX 1998
- Country
- NAAS China
- KPRX United States
- Employees
- NAAS N/A
- KPRX N/A
- Industry
- NAAS Other Specialty Stores
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NAAS Consumer Discretionary
- KPRX Health Care
- Exchange
- NAAS Nasdaq
- KPRX Nasdaq
- Market Cap
- NAAS 8.3M
- KPRX 9.1M
- IPO Year
- NAAS 2017
- KPRX N/A
- Fundamental
- Price
- NAAS $1.06
- KPRX $3.08
- Analyst Decision
- NAAS
- KPRX Strong Buy
- Analyst Count
- NAAS 0
- KPRX 1
- Target Price
- NAAS N/A
- KPRX $10.00
- AVG Volume (30 Days)
- NAAS 209.1K
- KPRX 1.3M
- Earning Date
- NAAS 07-23-2025
- KPRX 05-09-2025
- Dividend Yield
- NAAS N/A
- KPRX N/A
- EPS Growth
- NAAS N/A
- KPRX N/A
- EPS
- NAAS N/A
- KPRX N/A
- Revenue
- NAAS $43,258,393.00
- KPRX $20,000.00
- Revenue This Year
- NAAS $19.53
- KPRX N/A
- Revenue Next Year
- NAAS $151.36
- KPRX N/A
- P/E Ratio
- NAAS N/A
- KPRX N/A
- Revenue Growth
- NAAS 50.34
- KPRX N/A
- 52 Week Low
- NAAS $1.01
- KPRX $2.51
- 52 Week High
- NAAS $41.80
- KPRX $5.55
- Technical
- Relative Strength Index (RSI)
- NAAS 33.14
- KPRX 48.79
- Support Level
- NAAS $1.01
- KPRX $2.90
- Resistance Level
- NAAS $1.24
- KPRX $4.18
- Average True Range (ATR)
- NAAS 0.09
- KPRX 0.26
- MACD
- NAAS 0.04
- KPRX 0.00
- Stochastic Oscillator
- NAAS 16.92
- KPRX 19.12
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.